Eleven Therapeutics
Eleven Therapeutics is a biotechnology company pioneering the next generation of RNA therapeutics by combining synthetic chemistry and artificial intelligence. Founded in 2020, the company develops programmable RNA therapies that precisely silence disease-causing genes, focusing initially on respiratory diseases. Their platform uses massively parallel combinatorial chemistry and AI algorithms to explore the vast chemical space of RNA molecules, optimizing safety, efficiency, and duration of effect. Eleven Therapeutics operates collaborative hubs in Cambridge, UK; Boston, USA; and Tel Aviv, Israel, and partners with leading institutions such as the Vaccine Research Center at NIAID and Cambridge University. Their business model centers on developing scalable RNA therapeutic processes and collaborating with pharmaceutical and research partners to advance RNA-based gene therapies.
Eleven Therapeutics
Eleven Therapeutics is a biotechnology company pioneering the next generation of RNA therapeutics by combining synthetic chemistry and artificial intelligence. Founded in 2020, the company develops programmable RNA therapies that precisely silence disease-causing genes, focusing initially on respiratory diseases. Their platform uses massively parallel combinatorial chemistry and AI algorithms to explore the vast chemical space of RNA molecules, optimizing safety, efficiency, and duration of effect. Eleven Therapeutics operates collaborative hubs in Cambridge, UK; Boston, USA; and Tel Aviv, Israel, and partners with leading institutions such as the Vaccine Research Center at NIAID and Cambridge University. Their business model centers on developing scalable RNA therapeutic processes and collaborating with pharmaceutical and research partners to advance RNA-based gene therapies.